SYNERGY passed the on-site inspection by the U.S. FDA
SYNERGY underwent a cGMP on-site inspection by the U.S. FDA from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. The company recently confirmed that it has passed the inspection and complies with the U.S. FDA's cGMP management standards
According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that from August 4, 2025, to August 7, 2025, the company underwent an on-site inspection by the U.S. Food and Drug Administration ("U.S. FDA") for cGMP (current Good Manufacturing Practice). The inspection covered six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, the company learned from the U.S. FDA's official website that it has passed the aforementioned on-site inspection and complies with the U.S. FDA's cGMP management regulations
